Boston Common Asset Management LLC Trims Stock Holdings in AstraZeneca PLC (OTCMKTS:AZNCF)

Boston Common Asset Management LLC reduced its stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) by 17.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 216,775 shares of the company’s stock after selling 45,498 shares during the period. AstraZeneca comprises 0.8% of Boston Common Asset Management LLC’s holdings, making the stock its 24th biggest position. Boston Common Asset Management LLC’s holdings in AstraZeneca were worth $28,257,000 as of its most recent SEC filing.

Separately, Eagle Bay Advisors LLC bought a new position in AstraZeneca in the 3rd quarter worth $156,000. 40.87% of the stock is currently owned by institutional investors.

AstraZeneca Trading Up 1.8 %

AZNCF stock traded up $2.37 during trading on Friday, reaching $132.13. The company’s stock had a trading volume of 1,869 shares, compared to its average volume of 2,777. The company’s fifty day moving average is $131.41 and its 200-day moving average is $148.22. AstraZeneca PLC has a 1 year low of $118.16 and a 1 year high of $175.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.